Table 1. A comprehensive review of survival outcomes in HBV-associated ICC.
| Study | Study region |
Marker detection |
Patients (n) | Overall survival (%) | Median survival |
P value | Outcomes | |
|---|---|---|---|---|---|---|---|---|
| 1-yr | 5-yr | |||||||
| Zhang (2010) [50] HBV-ICC Non-HBV-ICC |
China | HBsAg/ HBcAb |
29 10 |
78.9 46.7 |
35.7 NR |
32 m | 0.025 | Favorable |
| Zhou (2011) [51] HBV-ICC Non-HBV-ICC |
China | HBsAg | 87 68 |
72.4 45.6 |
41.8 (3-yr) 20.5 (3-yr) |
NR | 0.003 | Favorable |
| Wu (2013) [53] HBV-ICC Non-HBV-ICC |
China | HBsAg/ HBcAb |
97 41 |
42 24 |
15 0 |
NR | 0.005 | Favorable |
| Liu (2013) [55] HBV-ICC Non-HBV-ICC |
China | HBsAg/ HBcAb |
37 23 |
45.9 30.4 |
15 (3-yr) 0 (3-yr) |
12 m 6 m |
0.017 | Favorable |
| Luo (2014) [38] HBV-ICC Non-HBV-ICC |
China | HBsAg | 608 725 |
NR NR |
NR NR |
19 m 12 m |
< 0.001 | Favorable |
| Wu (2015) [54] HBV-ICC |
China | HBsAg/ HBcAb |
85 | 60 | 13 | 25 m | NA | NA |
| Tao (2016) [28] HBV-ICC HBcAb-ICC Non-HBV-ICC |
China | HBsAg/ HBcAb |
39 (total) | 27.3 62.5 87.5 |
0 0 50 |
6.9 (mean) 17.0 (mean) 33.0 (mean) |
< 0.001 | Unfavorable |
| Ahn (2016) [5] HBV-ICC Non-HBV-ICC |
Korea | HBsAg | 37 255 |
NR | NR | NR | NS | No difference |
| Jeong [unpublished] HBV-ICC Non-HBV-ICC |
China | HBsAg | 56 64 |
72.2 50.0 |
46.5 (3-yr) 18.0 (3-yr) |
21 m 11 m |
0.001 | Favorable |
HBsAg: hepatitis B surface antigen, HBcAb: hepatitis B core antibody, NR: not reported, HBV-ICC: hepatitis B virus-associated intrahepatic cholangiocarcinoma, NA: not applicable, NS: not significant.